Novo Nordisk seeks EMA approval for 7.2 mg Wegovy dose after trials show 21% weight loss in people with obesity and type 2 diabetes.

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) ... or Wegovy, 1.7 milligrams or 2.4 milligrams.

Novo Nordisk (NVO) announced on Tuesday that it has submitted a new higher dose of its weight loss medication, Wegovy, to the European Medicines Agency for approval. The company is requesting approval ...

According to the Associated Press, trial participants received weekly injections of the highest tolerated doses of Zepbound, either 10 milligrams or 15 milligrams, or Wegovy, 1.7 milligrams or 2.4 ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial.

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.

In today’s Health Alert, two popular weight loss drugs went head-to-head in a clinical trial – and one came out on top. ... For Wegovy, that was either 1.7 or 2.4 milligrams.

The trial included 751 people from across the U.S. who were overweight or had obesity and at least one other weight-related health problem, ... or Wegovy, 1.7 milligrams or 2.4 milligrams.

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) over 72 weeks, while those who took semaglutide, or Wegovy, lost about 33 ...